Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) will be presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) taking place in San Diego (March 12-15, 2024). Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist, in development for prevention of AKI and hospital acquired infection.
Title: | Intravenous Gemini for Prevention of Acute Kidney Injury |
Presenter: | Robin Marsden, Senior Vice President of Biology, Revelation Biosciences |
Date/Time: | Tuesday, March 12, 2024 5:30 p.m. -7:30 p.m. Pacific Time |
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.